• Home
  • MyECTS
  • Become a member
  • Contact us

Ectsoc

Ecstoc.org

MENUMENU
  • About
    • Mission & Vision
    • Governance & Transparency
    • Board of Directors
    • Annual General Meeting
    • Committees and Action Groups
      • Executive Committee
      • Communications Committee
      • Community Engagement Committee
      • ECTS Academy
      • Education Committee
      • Clinical Science Committee
      • Research Committee
      • Scientific Programme Committee 2025
    • ECTS Team
    • Membership
      • Individual Membership
      • Corporate Supporters
      • Join us
      • Affiliated Societies
  • ECTS 2025
  • Events
    • Upcoming Congresses
    • Past Congress
    • ECTS Academy Charity Event
    • ICCBH
    • Events
  • Grants & Awards
  • Education
    • PhD Training Course
    • Clinical Training Course in Metabolic Bone Diseases
    • Rare Bone Diseases Webinars
    • Education Resource Center
    • Bone Muscle & Beyond Webinars
    • ECTS-Mellanby Training Course
    • Calendar ECTS Educational Events
  • ECTS Academy
    • About the ECTS Academy
    • ECTS Academy – Members
    • Call for Applications - Basic Scientists
    • Call for Applications - Clinicians
    • ECTS Academy Activities
      • NI Conference Program
      • ECTS Academy Webinar Series
      • ECTS Academy Mentoring Options
      • ECTS Academy Charity Run
    • Visit the ECTS Academy website
  • News
    • ECTS Newsletter
    • News
    • Press Release
    • Image Library
    • Video Library
    • Job Advertisements
You are here: Home / Boards / Cesar Libanati

Jun 19 2020

Cesar Libanati

Cesar Libanati MD.  Cesar received his medical degree with honors from the University of Buenos Aires Medical School, Argentina in 1982. He subsequently moved to the US and completed training and diplomacy in internal medicine and geriatrics. His early interest in skeletal metabolism lead to a research fellowship in Dr. David Baylink’s Mineral Metabolism Unit with who he remained associated for over two decades while on medical staff at Loma Linda University and the Veteran Administration.  He directed the Osteoporosis Research Center at Loma Linda and his research covered basic, translational and clinical osteoporosis and mineral metabolism with a particular emphasis on bone imaging. He has authored numerous research articles, book chapters and abstracts, is a member of professional skeletal societies and serves as a scientific reviewer in bone journals. In 2005 he joined the Bone Research and Development Group at Amgen, California where he advanced the development, registration and commercialization of denosumab for the treatment of osteoporosis. After 10 years at Amgen he joined UCB in Brussels to continue developing solutions for patients suffering from osteoporosis and fractures; leading to the recent approval of romosozumab for postmenopausal women with severe osteoporosis at high risk of fracture. His current position is Head, Medical External Affairs in the Bone Patient Value Unit at UCB Pharma.

Copyright 2016 ECTS - Disclaimer - Cookies Policy - Privacy Policy - Privacy Centre - Terms of use - Contact us